Bridge to Life and Tevosol Merge to Commercialize Portable Normothermic Machine Preservation Technology Platform for Organ Transplantation
NORTHBROOK, Ill. and EDMONTON, AB, Feb. 9, 2021 /PRNewswire/ -- Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life's significant financial commitment to manufacture, trial, and launch Tevosol's portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.
"We are pleased to welcome Tevosol into our growing organization and to champion their bold new approach to EVLP," said Bridge to Life CEO Stevan Schweighardt. "Together we can fulfill the great promise of this emerging clinical practice—and we're already working on exciting projects beyond lung transplantation and a host of other possibilities for the future. This strategic investment exemplifies our mission to serve the transplantation community by delivering a complete range of innovative organ preservation technologies."
Bridge to Life is also actively developing cold perfusion technologies for the kidney, liver, and heart. With nearly 1,000 candidates on the US lung transplant waiting list, the merger with Tevosol provides a new platform to increase the availability of donor lungs.
Tevosol, co-founded in 2015 by Drs. Darren Freed and Jayan Nagendran, developed the EVOSS™ Ex-Vivo Organ Support System to preserve, assess, and reclaim donor organs and completed its first human lung transplants in 2019 with results published in Nature Communications [doi.org/10.1038/s41467-020-19581-4]. EVOSS Lung pivotal clinical trials are scheduled to begin in 2021.
"Partnering with Bridge to Life, with their extensive global reach, robust technical support coverage, and clinical education programs, will allow Tevosol to reach more patients with this lifesaving technology," said Freed.
With this new partnership, Dr. Freed becomes Chief Scientific Officer and Dr. Nagendran assumes the Chief Medical Officer position at Bridge to Life. Ron Mills remains CEO of Tevosol, a d/b/a subsidiary Bridge to Life (Canada). EVOSS product research and development, engineering and design, and assembly and packaging are wholly based in Edmonton for worldwide export.
"We're eager to put this creative partnership to efficient use and boost our speed to market," said Mills, "and we're confident our machines can help procurement organizations deliver more donor organs to more surgeons for more lifesaving transplants."
About Bridge to Life
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. Bridge to Life is a leading supplier of preservation solutions globally worldwide with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, we continue to explore emerging science and preservation technologies. bridgetolife.com
About Tevosol
Tevosol, a Bridge to Life company, is developing EVOSS™ (Ex-Vivo Organ Support System), a portable and affordable warm perfusion machine to preserve, assess, and reclaim donor organs for lifesaving transplants. The company completed its first human lung transplants in 2019; secured financing and key strategic partnerships in 2020; and aims to manufacture, trial, and commercialize EVOSS Lung in 2021-22 and EVOSS Heart in 2023. tevosol.com
SOURCE Bridge to Life
Share this article